Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CytoDyn Inc.

< Previous 1 2 Next >
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Releases ESMO Breast Cancer Meeting Poster
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
March 2025 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
December 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
September 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Settlement with Amarex Clinical Research LLC
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn to Host Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
May 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces FDA Has Lifted Clinical Hold
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Announces Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
November 2023 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
Tickers CYDY
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.